• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预防性乳房切除术对 BRCA1/2 突变携带者的影响。

Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers.

机构信息

Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany.

出版信息

Breast Care (Basel). 2014 Dec;9(6):385-9. doi: 10.1159/000369592.

DOI:10.1159/000369592
PMID:25759620
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4317675/
Abstract

Unlike the general decrease in invasive oncologic care, the trend for prophylactic bilateral mastectomy in healthy women and prophylactic contralateral mastectomy in women with unilateral breast cancer is steadily rising. This is even more surprising when considering that for e.g. prophylactic contralateral mastectomy no clear survival benefit has been demonstrated so far. The decision-making process around risk-reducing surgery may be influenced by several conflicting parameters such as the patient's fears and desire to achieve a survival advantage, the surgeon's financial motivations, or the oncologist's paternalistic approach to the above trend. Physicians should support their patients throughout the decision-making process, guide them through the dense fog of information, and encourage them to reconsider all options and alternatives before embarking on an irreversible surgical intervention. Healthy and diseased women should be comprehensively informed about their absolute individual risks for cancer, the benefits and harms of the surgery, alternative preventive strategies, and last but not least the competing risks of preceding carcinomas and cancer in general. Within the framework of non-directive counseling in the specialized centers of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), decision-making aids are being developed with grants from the Federal Ministry of Health and the German Cancer Aid to support women in making conclusive and satisfactory decisions.

摘要

与普通的侵入性肿瘤治疗减少的趋势相反,健康女性预防性双侧乳房切除术和单侧乳腺癌女性预防性对侧乳房切除术的趋势正在稳步上升。当考虑到例如预防性对侧乳房切除术迄今尚未显示出明确的生存获益时,这一点更加令人惊讶。风险降低手术的决策过程可能受到多种相互冲突的因素的影响,例如患者的恐惧和获得生存优势的愿望、外科医生的经济动机,或肿瘤学家对上述趋势的家长式方法。医生应在整个决策过程中支持患者,引导他们了解信息的迷雾,并鼓励他们在进行不可逆转的手术干预之前重新考虑所有选择和替代方案。健康和患病的女性应全面了解其患癌症的绝对个体风险、手术的益处和危害、替代预防策略,最后但同样重要的是,要了解先前的癌前病变和一般癌症的风险。在德国遗传性乳腺癌和卵巢癌(GC-HBOC)专门中心的非指导性咨询框架内,正在利用联邦卫生部和德国癌症援助的赠款开发决策辅助工具,以支持女性做出明确和满意的决策。

相似文献

1
Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers.预防性乳房切除术对 BRCA1/2 突变携带者的影响。
Breast Care (Basel). 2014 Dec;9(6):385-9. doi: 10.1159/000369592.
2
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.BRCA 突变携带者的双侧预防性乳房切除术:外科医生需要了解的内容。
Ann Ital Chir. 2019;90:1-2.
3
Breast cancer treatment in mutation carriers: surgical treatment.突变携带者的乳腺癌治疗:手术治疗
Minerva Ginecol. 2016 Oct;68(5):548-56. Epub 2016 Jan 28.
4
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.乳腺癌以及携带BRCA1或BRCA2基因突变的女性通过癌症预防策略所获得的预期寿命提升。
JAMA. 2000 Feb 2;283(5):617-24. doi: 10.1001/jama.283.5.617.
5
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.在一组前瞻性队列中,对未受影响的BRCA1和BRCA2基因突变携带者进行双侧预防性卵巢切除术和双侧预防性乳房切除术。
Clin Breast Cancer. 2007 Dec;7(11):875-82. doi: 10.3816/CBC.2007.n.053.
6
One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).对选择进行BRCA1和BRCA2基因症状前检测的女性的一年随访:检测结果的情感影响及风险管理决策(监测或预防性手术)
Breast Cancer Res Treat. 2002 May;73(2):97-112. doi: 10.1023/a:1015269620265.
7
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.携带BRCA1或BRCA2基因突变女性对侧预防性乳房切除术的预测因素:遗传性乳腺癌临床研究组
J Clin Oncol. 2008 Mar 1;26(7):1093-7. doi: 10.1200/JCO.2007.12.6078. Epub 2008 Jan 14.
8
Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.塔斯马尼亚州携带BRCA1和BRCA2基因突变女性的癌症风险管理
Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
9
Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.决策辅助工具对女性 BRCA1 和 BRCA2 基因突变携带者有效性的系统评价。
BMC Med Inform Decis Mak. 2019 Aug 1;19(1):154. doi: 10.1186/s12911-019-0872-2.
10
Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.接受双侧预防性乳房切除术的女性对乳腺癌风险的认知。
J Natl Cancer Inst. 2002 Oct 16;94(20):1564-9. doi: 10.1093/jnci/94.20.1564.

引用本文的文献

1
Prepectoral breast reconstruction with complete anterior implant coverage using a single, large, square-shaped acellular dermal matrix.采用单个大正方形去细胞真皮基质进行完全前侧覆盖的胸肌前置乳房重建。
BMC Surg. 2022 Jun 20;22(1):234. doi: 10.1186/s12893-022-01683-z.
2
Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriers - adaptation and pilot testing of a curriculum for nurses: a qualitative study.由专业护士为健康的BRCA1/2基因突变携带者提供的以护士为主导的决策指导——护士课程的改编与试点测试:一项定性研究
BMC Nurs. 2022 Feb 10;21(1):42. doi: 10.1186/s12912-022-00810-8.
3
Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.印度遗传性乳腺癌和卵巢癌综合征的遗传咨询、检测与管理:印度医学与儿科肿瘤学会专家共识文件
JCO Glob Oncol. 2020 Jul;6:991-1008. doi: 10.1200/JGO.19.00381.
4
Hereditary breast cancer: screening and risk reducing surgery.遗传性乳腺癌:筛查与降低风险的手术
Gland Surg. 2019 Sep;8(Suppl 3):S142-S149. doi: 10.21037/gs.2019.04.04.
5
Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.双侧预防性乳房切除术和输卵管卵巢切除术的成本效益。
Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
6
Surgical Treatment of Breast Cancer in BRCA-Mutation Carriers.携带BRCA基因突变的乳腺癌患者的手术治疗
J Breast Health. 2015 Jul 1;11(3):101-105. doi: 10.5152/tjbh.2015.0001. eCollection 2015 Jul.
7
Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome.遗传性乳腺癌-卵巢癌综合征中的加速衰老进程
Oncotarget. 2016 Mar 15;7(11):11959-71. doi: 10.18632/oncotarget.7867.

本文引用的文献

1
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.BRCA1 和 BRCA2 基因突变携带者的乳腺癌对侧乳房切除术与生存:回顾性分析。
BMJ. 2014 Feb 11;348:g226. doi: 10.1136/bmj.g226.
2
The Angelina effect: immediate reach, grasp, and impact of going public.安吉丽娜效应:上市的即时影响力。
Genet Med. 2014 Jul;16(7):516-21. doi: 10.1038/gim.2013.181. Epub 2013 Dec 19.
3
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.BRCA1 和 BRCA2 突变携带者的癌症风险:EMBRACE 前瞻性分析的结果。
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.
4
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.与BRCA1或BRCA2基因阳性家族的患者相比,BRCA1/2基因阴性的高危家族患者发生对侧乳腺癌的风险:一项回顾性队列研究。
Breast Cancer Res. 2012 Dec 7;14(6):R156. doi: 10.1186/bcr3369.
5
Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.遗传性乳腺癌和卵巢癌:新基因、新疗法、新概念。
Dtsch Arztebl Int. 2011 May;108(19):323-30. doi: 10.3238/arztebl.2011.0323. Epub 2011 May 13.
6
Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.临床管理因素影响对侧预防性乳房切除术的决策。
J Clin Oncol. 2011 Jun 1;29(16):2158-64. doi: 10.1200/JCO.2010.29.4041. Epub 2011 Apr 4.
7
Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.乳腺癌病理的家族一致性作为多病例家族中基因型的指标。
Genes Chromosomes Cancer. 2010 Dec;49(12):1082-94. doi: 10.1002/gcc.20816.
8
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.BRCA1 或 BRCA2 基因突变携带者的降低风险手术与癌症风险和死亡率的关联。
JAMA. 2010 Sep 1;304(9):967-75. doi: 10.1001/jama.2010.1237.
9
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.奥拉帕利在携带 BRCA1 或 BRCA2 突变的复发性卵巢癌患者中的疗效:一项概念验证试验。
Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6.
10
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.奥拉帕利治疗携带 BRCA1 或 BRCA2 突变的晚期乳腺癌患者的疗效:一项概念验证试验。
Lancet. 2010 Jul 24;376(9737):235-44. doi: 10.1016/S0140-6736(10)60892-6. Epub 2010 Jul 6.